Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma for whom enucleation has been recommended.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces research collaboration with Attmos
- Cautious Hold Rating on IDEAYA Biosciences Amid Anticipated Equity Raises and Financial Pressures
- IDEAYA Biosciences Reports 2024 Financials and Business Update
- IDEAYA Biosciences: Strategic Advancements and Promising Clinical Developments Support Buy Rating
- Strategic Advancements and Clinical Progress Drive IDEAYA Biosciences’ Buy Rating